Publications by authors named "Cuimin Ding"

Claim this Profile
S
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.
Hua Zhong, Shunjun Jiang, Wenxiu Yao, Xia Song, Dongqing Lv, Cuimin Ding

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The inhibitory effect of M2 macrophage-derived exosomes on gefitinib resistant lung adenocarcinoma cells through the MIF/TIMP1/CD74 axis.
Jingcui Peng, Yan Zhang, Bin Li, Xin He, Cuimin Ding

Sci Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.
Yuequan Shi, Xiaoyan Liu, Anwen Liu, Jian Fang, Qingwei Meng, Cuimin Ding

Chin Med J (Engl)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial.
Yuankai Shi, Minghong Bi, Qingshan Li, Guolei Wang, Jianhua Chen, Cuimin Ding

Cancer Pathog Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.
Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, Ludovic Doucet, Jianying Zhou, Cuimin Ding

Cell Rep Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations.
Xiaobei Guo, Hui Zhang, Yuequan Shi, Qi He, Anwen Liu, Cuimin Ding

Transl Lung Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial.
Tianqing Chu, Hua Zhong, Zhuang Yu, Jing Wang, Yanqiu Zhao, Cuimin Ding

Cancer Commun (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.
Xinyue Wang, Zhaona Li, Liuchun Wang, Yan Liang, Chun Huang, Dingzhi Huang, Cuimin Ding

BMC Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of finotonlimab plus docetaxel docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial.
Baohui Han, Lin Wu, Runxiang Yang, Hongbo Wu, Wei Li, Cuimin Ding

Transl Lung Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
Ying Cheng, Wei Zhang, Lin Wu, Caicun Zhou, Donglin Wang, Cuimin Ding

JAMA Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Cuimin Ding

J Immunother Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.
Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Cuimin Ding

Lancet Respir Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Cuimin Ding, Lieming Ding

Lung Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
Mengzhao Wang, Yun Fan, Meili Sun, Yongsheng Wang, Yanqiu Zhao, Cuimin Ding

Lancet Respir Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mRNA of solute carrier family 22, member 17 (SLC22A17) plays the potential diagnostic and prognostic role in advantage non-small cell lung cancer patients.
Wenwen Qin, Cuimin Ding, Fei Peng, Ping Wang

Ann Biol Clin (Paris)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difference of serum tumor markers in different clinical stages of elderly patients with non-small cell lung cancer and evaluation of diagnostic value.
Wen Wen Qin, Ping Wang, CuiMin Ding, Fei Peng

J Med Biochem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Shun Lu, Lin Wu, Hong Jian, Ying Cheng, Qiming Wang, Cuimin Ding

Lancet Respir Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Cuimin Ding

J Thorac Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomes derived from M1 macrophages inhibit the proliferation of the A549 and H1299 lung cancer cell lines via the miRNA-let-7b-5p-GNG5 axis.
Jingcui Peng, Sa Li, Bin Li, WenXia Hu, Cuimin Ding

PeerJ· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung infection caused by Blastoschizomyces capitatus without immunodeficiency: a case report and review of the literature.
Jingcui Peng, Bin Li, Xin He, Cuimin Ding

Ann Palliat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Cuimin Ding, Lieming Ding

J Thorac Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Shun Lu, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Cuimin Ding

Lancet Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.
Xin He, Yaqian Chi, Jingcui Peng, Wenxia Hu, Cuimin Ding

J Thorac Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of autoantibody detection in the diagnosis and staging of lung cancer.
Yun Wang, Yang Jiao, Cui-Min Ding, Wu-Zhuang Sun

Ann Transl Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-associated eosinophilia in a patient with -positive, -amplified lung adenocarcinoma refractory to targeted therapy: a case report and review of literature.
Nan Geng, Wenxia Hu, Hui Ge, Shaonan Xie, Cuimin Ding

Transl Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis